section name header

Pronunciation ⬇

dal-TE-pa-rin

Classifications ⬆ ⬇

Therapeutic Classification: anticoagulants

Pharmacologic Classification: antithrombotics, low molecular weight heparins

Indications ⬆ ⬇

High Alert


Action ⬆ ⬇

  • Potentiates the inhibitory effect of antithrombin on factor Xa and thrombin.
Therapeutic effects:
  • Prevention of thrombus formation.
  • Decreased incidence of death or recurrent MI.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (87%) after SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 2.1–2.3 hr.

Time/Action Profile ⬆ ⬇

(antithrombotic effect)

ROUTEONSETPEAKDURATION
SUBQrapid4 hrup to 24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: reversible ↑ in liver enzymes

Hemat: bleeding, thrombocytopenia

Neuro: dizziness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

DVT Prophylaxis

Extended Treatment of Symptomatic VTE in Patients with Cancer

Renal Impairment

Angina/Non ST-Segment-Elevation MI

Treatment of Symptomatic VTE

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Fragmin

Code ⬆

NDC Code